Enthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia. Recent changes have reignited interest in the region, with important implications for pharma executives.
{iframe}https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/asia-on-the-move-five-trends-shaping-the-asia-biopharmaceutical-market?cid=other-eml-alt-mip-mck-oth-1805&hlkid=c1358ce533af4f9faa102b05b5e9ee2c&hctky=3027237&hdpid=457c4c76-f95c-43fa-8005-a3deca9ce90c{/iframe}